sponsored content November 1, 2023 By Erin S. Tomiyama, OD, PhD, FAAO Most compounding pharmacies are small and do not have the...
August 1, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE Eye care professionals frequently prescribe topical low-dose atropine to slow myopic...
July 5, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE Most published myopia clinical trials study a single intervention versus control,...
June 15, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE In a new study recently published in JAMA Ophthalmology, a novel preservative-free...
June 6, 2023 BRIDGEWATER, N.J. — The U.S. Food and Drug Administration (FDA) has accepted Vyluma’s new drug application (NDA) for its...
May 3, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE A gold mine for cutting-edge myopia research, the ARVO Meeting, held...
DUBLIN – The World Society of Paediatric Ophthalmology and Strabismus has released its Myopia Consensus Statement 2023. The document details the interventions...
March 1, 2023 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE Low concentration (0.01% to 0.05%) atropine effectively slows myopia progression in...
March 1, 2023 By Peter (Zhi) Chen, MD, PhD, Fudan University Eye and ENT Hospital, Shanghai, China Low-concentration atropine is needed only...
February 15, 2023 NASHVILLE, Tenn. — U.S. pharmaceutical company Harrow has released its compounded, patent-pending formulas of low-dose atropine. Eye care professionals...
December 15, 2022 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE Several clinical trials (Kinoshita et al., Kinoshita et al., Tan et...
December 1, 2022 By Thomas Aller, OD, FBCLA There are advantages to being creative when controlling the progression of myopia in children...
sponsored content October 27, 2022 Vyluma aims to preserve the vision of a global population by providing meaningful and effective pharmaceutical ophthalmic...
October 17, 2022 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FBCLA Topical low-concentration atropine is widely prescribed for myopia progression control in...
October 3, 2022 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE Many eye care professionals have expressed concern about rebound after children...
October 3, 2022 By Krupa Philip, B.Optom, PhD, Senior Research Scientist at BHVI Depending on the strategy, there are some additional considerations...
September 1, 2022 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE The aim of the atropine combined with orthokeratology (AOK) study was...
July 1, 2022 By Katherine Schuetz, OD We have an ever-growing armamentarium for myopia control; educate your patients and their parents about...
June 1, 2022 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE The International Myopia Institute’s white paper on Defining and Classifying Myopia...
April 15, 2022 By David Anderson, OD If I could say anything to a doctor who might ask me what to do...
April 1, 2022 By Geetha Sravani, PhD Candidate, Brien Holden Vision Institute Myopia prevalence is high in many Asian countries. To delay...
March 1, 2022 By Linh Hoang, MD, MSc, and Huy Tran, MD, PhD Atropine and orthokeratology are effective in slowing myopia. Despite...
March 1, 2022 By Dr. Pavan K. Verkicharla and Mr. Swapnil Thakur It is important to note that there will be non-responders...
January 17, 2022 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE The aim of this clinical trial conducted in Hong Kong on...
No one treatment is 100% effective at slowing the rate of myopia progression.
April 15, 2021 By Dwight Akerman, OD, FAAO, FBCLA The LAMP study (low-concentration atropine for myopia progression) from Hong Kong addressed safety...
A summary of the LAMP Study results